MBRX (Moleculin Biotech) YoY EBITDA Growth : 35.77% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Moleculin Biotech's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 35.77%.

Moleculin Biotech's EBITDA per Share for the three months ended in Sep. 2024 was $-1.91.

Moleculin Biotech YoY EBITDA Growth Historical Data

The historical data trend for Moleculin Biotech's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech YoY EBITDA Growth Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

26.19

22.28

57.28

-26.39

6.69

Moleculin Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EBITDA Growth	Get a 7-Day Free Trial															37.22	-19.71	37.93	24.94	35.77

Moleculin Biotech YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Moleculin Biotech's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-15.007	-	-16.083)	/	\| -16.083 \|
=	6.69 %

Moleculin Biotech's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2024 )
=	(EBITDA per Share (Q: Sep. 2024 )	-	EBITDA per Share (Q: Sep. 2023 ))	/	\| EBITDA per Share (Q: Sep. 2023 )) \|
=	(-1.912	-	-2.977)	/	\| -2.977 \|
=	35.77 %

Moleculin Biotech YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

0K2H:UK

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Executives

Jonathan P. Foster	officer: Exec. Vice President and CFO	2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp	director, 10 percent owner, officer: Chairman and Acting CEO	1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco	director	PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker	10 percent owner, officer: President and COO
Michael D Cannon	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth	officer: Chief Financial Officer	2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380